Dosage Forms

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Sample dilution, sensitivity, excipient interference, and containment are key issues that must be addressed.

Overcoming Analytical Challenges in High Potency Formulation

Feliza Mirasol is the science editor for 

API supplier Olon has started construction of a new manufacturing facility in Milan, Italy, which will be dedicated to production of cytotoxic payloads and linkers for ADCs.

Olon Makes Headway into ADCs Market with New Manufacturing Facility in Italy

The new guidance provides detailed recommendations to drug developers with a target of helping to ensure that drug developers provide adequate information to assess potency at each stage of a product’s life cycle. 

FDA Issues Guidance on Potency for mAbs and Therapeutic Proteins

Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.



Catalent Expands its High Potency Micronization Capabilities in both US and UK

CordenPharma will build a clinical trial development facility for manufacture of oral solid dosage drug products at its Plankstadt facility near Heidelberg, Germany.

CordenPharma Adds Highly Potent Capabilities in Germany

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Richard Denk, Senior Consultant Aseptic Processing and Containment, SKAN AG, discusses the evolution of aseptic processing with a particular focus on isolators.

Evolution of Aseptic Processing: INTERPHEX Keynote Part 2

The new lab near Continuus Pharmaceutical’s current facilities in Massachusetts will expand the company’s process development capabilities to high-potency drugs.

Continuus Pharmaceuticals Opens Process Development Lab

In addition to ADCs, other types of highly potent biologics require specialized manufacturing skills.

Assessing Risk and Production of Potent Substances

The company will expand its micronization abilities for highly potent drug compounds through this investment. 

Catalent to Invest $10 Million to Increase Isolator Capabilities at US and UK Sites

Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.

Highly Potent Drugs